ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is delighted to announce that its Parsortix system has been formally adopted in the ongoing European wide GANNET53 drug trial, an ...

GUILDFORD, SURREY / ACCESSWIRE / December 12, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce the presentation of two posters at the San Antonio ...

Guildford, Surrey, UK - September 21, 2015 - Research conducted at Barts Cancer Institute, Queen Mary University, London, published today in PLOS ONE demonstrates that the Parsortix Cell Separation ...

University of Athens, Attikon University Hospital, Greece first to demonstrate use of the Parsortix system in head and neck cancer ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is ...

GUILDFORD, SURREY / ACCESSWIRE / September 26, 2024 / Whole Genomic Sequencing and machine learning identifies key cancer genes associated with DNA proliferation and repair ANGLE plc ...

GUILDFORD, UNITED KINGDOM--(Marketwired - Oct 9, 2017) - Angle PLC (OTCQX: ANPCY) (AIM: AGL) AIM: AGL; OTCQX: ANPCY For immediate release 9 October 2017 ANGLE plc ("the Company") ANGLE'S PARSORTIX™ ...

After more than six years of development, Angle has scored an FDA approval for Parsortix as a diagnostic for metastatic breast cancer – the first ever in the US for a device used to detect cancer by ...

A rigorous evaluation by researchers at University Medical Centre Hamburg-Eppendorf (UKE) of ANGLE’s ParsortixTM cell separation system has demonstrated significant advantages of its size and ...

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce the publication of a five year programme of work undertaken by the CANCER-ID Consortium to establish the ...

ANGLE'S PARSORTIX SYSTEM KEY TO STUDY DEMONSTRATING RNA ANALYSIS OF CTCs AS A PROGNOSTIC TOOL IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS Research published by world-class cancer research centre ...

FDA and EU filings for blood-based circulating tumor cell diagnostic are projected for 2013. Cancer diagnostics firm Parsortix signed a two-year agreement with the Cancer Research UK-funded Paterson ...